[go: up one dir, main page]

SG11201604738TA - Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof - Google Patents

Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Info

Publication number
SG11201604738TA
SG11201604738TA SG11201604738TA SG11201604738TA SG11201604738TA SG 11201604738T A SG11201604738T A SG 11201604738TA SG 11201604738T A SG11201604738T A SG 11201604738TA SG 11201604738T A SG11201604738T A SG 11201604738TA SG 11201604738T A SG11201604738T A SG 11201604738TA
Authority
SG
Singapore
Prior art keywords
antigen
antibody
binding fragment
medical application
medical
Prior art date
Application number
SG11201604738TA
Inventor
Jijun Yuan
Xiangdong Qu
Jufang Lin
Xin Ye
Guoqing Cao
Weikang Tao
Lianshan Zhang
Lei Zhang
Li Yang
Original Assignee
Shanghai Hengrui Pharm Co Ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53370605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201604738T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Hengrui Pharm Co Ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai Hengrui Pharm Co Ltd
Publication of SG11201604738TA publication Critical patent/SG11201604738TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201604738TA 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof SG11201604738TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310681942 2013-12-12
PCT/CN2014/091090 WO2015085847A1 (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Publications (1)

Publication Number Publication Date
SG11201604738TA true SG11201604738TA (en) 2016-07-28

Family

ID=53370605

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201604738TA SG11201604738TA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SG10201804945WA SG10201804945WA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201804945WA SG10201804945WA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Country Status (36)

Country Link
US (2) US10344090B2 (en)
EP (1) EP3081576B1 (en)
JP (1) JP6502959B2 (en)
KR (1) KR102256152B1 (en)
CN (1) CN105026428B (en)
AU (1) AU2014361473B2 (en)
BR (1) BR112016013338B1 (en)
CA (1) CA2932966C (en)
CL (1) CL2016001460A1 (en)
CR (1) CR20160319A (en)
CY (1) CY1122245T1 (en)
DK (1) DK3081576T3 (en)
DO (1) DOP2016000133A (en)
EA (1) EA035037B1 (en)
EC (1) ECSP16060104A (en)
ES (1) ES2746805T3 (en)
HK (1) HK1213910A1 (en)
HR (1) HRP20191678T1 (en)
HU (1) HUE046249T2 (en)
IL (1) IL246137B (en)
LT (1) LT3081576T (en)
ME (1) ME03527B (en)
MX (1) MX370449B (en)
MY (1) MY184154A (en)
PE (1) PE20160953A1 (en)
PH (1) PH12016501120B1 (en)
PL (1) PL3081576T3 (en)
PT (1) PT3081576T (en)
RS (1) RS59480B1 (en)
SG (2) SG11201604738TA (en)
SI (1) SI3081576T1 (en)
SM (1) SMT201900591T1 (en)
TW (1) TWI654201B (en)
UA (1) UA119659C2 (en)
WO (1) WO2015085847A1 (en)
ZA (1) ZA201604660B (en)

Families Citing this family (389)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378407T3 (en) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Increased expression of human or humanized immunoglobulin in non-human transgenic animals
KR20190069615A (en) 2008-12-09 2019-06-19 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
PL3409278T3 (en) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SG11201604738TA (en) * 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR102248804B1 (en) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
SI3116909T1 (en) 2014-03-14 2020-03-31 Novartis Ag Antibody molecules to lag-3 and uses thereof
MX2017003227A (en) 2014-09-13 2017-12-04 Novartis Ag Combination therapies of alk inhibitors.
CA2957491A1 (en) 2014-09-16 2016-03-24 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR102536786B1 (en) 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Cd73 blockade
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
ES2803655T3 (en) 2015-05-29 2021-01-28 Agenus Inc Anti-ctla-4 antibodies and methods of using them
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
DK3981792T3 (en) 2015-07-30 2024-09-02 Macrogenics Inc PD-1 binding molecules and methods of use thereof
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP6868862B2 (en) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 Mesoporous silica particles
MA48579A (en) 2015-09-01 2020-03-18 Agenus Inc ANTI-PD1 ANTIBODIES AND METHODS OF USING THEM
WO2017054646A1 (en) * 2015-09-28 2017-04-06 江苏恒瑞医药股份有限公司 Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
RU2722451C1 (en) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 antibodies and use thereof
US10428145B2 (en) * 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
EP4105235A1 (en) 2015-10-02 2022-12-21 Symphogen A/S Anti-pd-1 antibodies and compositions
CR20180161A (en) 2015-10-02 2018-05-25 Hoffmann La Roche Bispecific Antibodies for PD1 and TIM3
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
WO2017072208A1 (en) * 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Transgenic rabbit with common light chain
BR112018008867A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and their uses
WO2017084495A1 (en) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof
GEP20217220B (en) 2015-11-18 2021-02-10 Merck Sharp & Dohme Pd1 and/or lag3 binders
CN109152798B (en) 2015-12-02 2022-10-21 斯特库比股份有限公司 Antibodies specific for glycosylated PD-1 and methods of use thereof
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
SG10202000645SA (en) 2016-01-21 2020-03-30 Innate Pharma Neutralization of Inhibitory Pathways in Lymphocytes
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
CN108699158B (en) 2016-03-08 2022-06-03 依奈特制药公司 Siglec neutralizing antibodies
CN109071636A (en) 2016-03-29 2018-12-21 斯特库比股份有限公司 Method for selecting the antibody of specific binding glycosylation immunologic test point albumen
EP3436829A1 (en) 2016-03-30 2019-02-06 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
BR112018072986A2 (en) * 2016-05-18 2019-03-06 Boehringer Ingelheim International Gmbh anti-pd-1 and anti-lag3 antibodies for cancer treatment
CN105968200B (en) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti human PD-L 1 Humanized monoclonal antibodies and its application
CN106008714B (en) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti-human PD-1 Humanized monoclonal antibodies and its application
SG10201912563XA (en) 2016-05-27 2020-02-27 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
SMT202300290T1 (en) 2016-06-02 2023-11-13 Bristol Myers Squibb Co Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
SG11201810454YA (en) 2016-06-02 2018-12-28 Bristol Myers Squibb Co Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
KR20190015407A (en) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 Anti-PD-1 antibody for use in the treatment of recurrent small cell lung cancer
KR102702675B1 (en) 2016-06-03 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
JP2019517511A (en) 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-PD-1 antibody for use in a method of treating a tumor
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
BR112018076281A2 (en) 2016-06-20 2019-03-26 Kymab Limited immunocytocin, use of an immunocytocin, method, pharmaceutical composition, method for treating a proliferative disease in an animal, nucleic acid, vector, host and antibody or fragment thereof
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
CN106967172B (en) * 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (en) 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CN109952316A (en) 2016-09-14 2019-06-28 北京韩美药品有限公司 A kind of antibody and its function fragment that can specifically combine PD-1
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
TWI764943B (en) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer
TWI773694B (en) 2016-10-11 2022-08-11 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
CN108778332B (en) * 2016-10-21 2019-10-18 苏州盛迪亚生物医药有限公司 PD-1 antibody is combined with IDO inhibitor is preparing the purposes in anti-tumor drug
EP4491237A3 (en) 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
MA46724A (en) 2016-11-01 2021-04-21 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH 1 (PD -1)
MA46708B1 (en) 2016-11-02 2021-10-29 Jounce Therapeutics Inc Anti-pd1 antibodies and their uses
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
AU2017356860A1 (en) * 2016-11-08 2019-05-16 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108079292A (en) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 A kind of purposes of anti-PD-1 antibody in the drug for preparing treatment liver cancer
EA201991383A1 (en) 2016-12-07 2019-12-30 Эйдженус Инк. ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
MA50948A (en) 2016-12-07 2020-10-14 Agenus Inc ANTIBODIES AND METHODS OF USING THE SAME
JP7211952B2 (en) 2017-01-05 2023-01-24 ネトリス ファーマ Combination treatment with netrin-1 inhibitors and immune checkpoint inhibitors
WO2018129559A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
ES2902670T3 (en) * 2017-01-13 2022-03-29 Taizhou Hanzhong Biopharmaceutics Inc Monoclonal antibody against PD-1 and applications thereof
CN110198954A (en) 2017-01-13 2019-09-03 艾吉纳斯公司 T cell receptor and its application method in conjunction with NY-ESO-1
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
CN110291109B (en) * 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 Monoclonal antibody to human programmed death receptor PD-1 and its fragments
CN108341871A (en) 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 Anti- PD-1 monoclonal antibodies and its preparation method and application
CN108387731A (en) * 2017-02-03 2018-08-10 武汉三鹰生物技术有限公司 A kind of enzyme linked immunosorbent detection and preparation method for people's PD1 albumen
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US11078191B2 (en) 2017-02-10 2021-08-03 Novartis Ag 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer
TWI674261B (en) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 modulators
WO2018160540A1 (en) 2017-02-28 2018-09-07 Sanofi Therapeutic rna
JP7308150B2 (en) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム Compositions and methods for treating cancer
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
AU2018247765B2 (en) 2017-04-03 2023-11-23 F. Hoffmann-La Roche Ag Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
CN114984209A (en) 2017-04-05 2022-09-02 西福根有限公司 Combination therapy targeting PD-1, TIM-3 and LAG-3
PT3606955T (en) 2017-04-05 2025-01-09 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
TWI842672B (en) 2017-04-13 2024-05-21 美商艾吉納斯公司 Anti-cd137 antibodies and methods of use thereof
CN106939049B (en) 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 The monoclonal antibody and the preparation method and application thereof of antagonism inhibition people PD-1 antigen and its ligand binding
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
TWI805582B (en) 2017-05-01 2023-06-21 美商艾吉納斯公司 Anti-tigit antibodies and methods of use thereof
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
KR20200010500A (en) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 A composition comprising a combination of anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapy agents
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
DK3631454T3 (en) 2017-05-30 2023-12-04 Bristol Myers Squibb Co TREATMENT OF LAYER-3 POSITIVE TUMORS
JOP20190279A1 (en) 2017-05-31 2019-11-28 Novartis Ag Crystalline images of 5-bromo-2,6-dye (1H-pyrazole-1-yl) pyrimidine-4-amine and novel salts
CN117462668A (en) 2017-06-01 2024-01-30 百时美施贵宝公司 Methods of treating tumors with anti-PD-1 antibodies
EP3634995A4 (en) 2017-06-05 2021-06-09 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
WO2018223923A1 (en) * 2017-06-05 2018-12-13 江苏恒瑞医药股份有限公司 Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
CA3061874A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CR20190593A (en) 2017-06-22 2020-05-10 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015738A (en) 2017-06-27 2020-02-20 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof.
WO2019011855A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
KR102698385B1 (en) 2017-07-14 2024-08-22 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 regulator
EP3655023A1 (en) 2017-07-20 2020-05-27 Novartis AG Dosage regimens of anti-lag-3 antibodies and uses thereof
JP7186764B2 (en) 2017-07-28 2022-12-09 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
UY37829A (en) 2017-08-03 2019-01-31 Amgen Inc INTERLEUCINE MUTEINS 21 AND TREATMENT METHODS
JP7208225B2 (en) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
JP7316263B2 (en) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
KR102651946B1 (en) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotides as anticancer agents
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
BR112020006809A2 (en) 2017-10-06 2020-10-06 Innate Pharma antibodies, agent, use, compound, pharmaceutical composition, kits and composition or use
CN111344297B (en) 2017-10-10 2023-10-20 百时美施贵宝公司 Cyclic dinucleotides as anticancer agents
WO2019072220A1 (en) * 2017-10-13 2019-04-18 江苏恒瑞医药股份有限公司 Use of pd-1 antibody combined with epigenetic regulator in preparation of drug for treating tumors
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3697801B1 (en) 2017-10-16 2024-11-20 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
TW201916890A (en) * 2017-10-17 2019-05-01 大陸商江蘇恆瑞醫藥股份有限公司 Combination use of anti-PD-1 antibody and anti-LAG-3 antibody in the preparation of a medicament for the treatment of tumor
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
AU2018360790A1 (en) 2017-11-06 2020-06-11 Bristol-Myers Squibb Company Methods of treating a tumor
CN111655288A (en) 2017-11-16 2020-09-11 诺华股份有限公司 Combination therapy
WO2019096194A1 (en) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Use of pd-1 antibody combined with vegfr inhibitor in treatment of small cell lung cancer
CN109793892B (en) * 2017-11-16 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody in preparation of medicine for treating esophageal cancer
TWI814752B (en) * 2017-11-17 2023-09-11 大陸商江蘇恆瑞醫藥股份有限公司 Uses of immunotherapy agents, nucleoside antimetabolites combined with platinum in the preparation of drugs for treating tumor
CN109806393B (en) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, pemetrexed and platinum drugs in combined treatment of non-small cell lung cancer
CN111727373A (en) 2017-11-30 2020-09-29 诺华股份有限公司 Chimeric antigen receptor targeting BCMA and uses thereof
CN111246881B (en) * 2017-12-14 2023-03-10 江苏恒瑞医药股份有限公司 Use of PD-1 antibodies for treating tumors
TW201929900A (en) 2017-12-29 2019-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Uses of PD-1 antibody combined with apatinib for treating triple-negative breast cancer
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
CN110013552B (en) * 2018-01-08 2023-03-10 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, gemcitabine and platinum drug combination in treating malignant biliary tract tumor
EP3737694B1 (en) 2018-01-12 2023-03-01 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
AU2019209435A1 (en) 2018-01-22 2020-09-17 Bristol-Myers Squibb Company Compositions and methods of treating cancer
EP3743061A1 (en) 2018-01-22 2020-12-02 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019151771A1 (en) * 2018-02-02 2019-08-08 주식회사 뉴라클제네틱스 Pd-1 variant having improved binding to pd-l1
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
ES2980374T3 (en) 2018-03-08 2024-10-01 Bristol Myers Squibb Co Cyclic dinucleotides as anticancer agents
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN110272491B (en) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 Purification process of anti-PD-1 antibody
TWI841554B (en) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN111971306A (en) 2018-03-30 2020-11-20 百时美施贵宝公司 Method for treating tumors
CN112292399A (en) 2018-04-04 2021-01-29 百时美施贵宝公司 anti-CD27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112074516A (en) 2018-04-25 2020-12-11 先天肿瘤免疫公司 NLRP3 modulators
TW202012430A (en) 2018-04-26 2020-04-01 美商艾吉納斯公司 Heat shock protein-binding peptide compositions and methods of use thereof
KR20210006353A (en) 2018-05-04 2021-01-18 톨리스 TLR3 ligand that activates both epithelial and bone marrow cells
JP7519907B2 (en) 2018-05-07 2024-07-22 ジェンマブ エー／エス Methods for treating cancer using a combination of anti-PD-1 antibody and anti-tissue factor antibody-drug conjugate
KR20210010998A (en) 2018-05-17 2021-01-29 난징 리즈 바이오랩스 씨오., 엘티디. Antibody binding PD 1 and uses thereof
CN110507820A (en) * 2018-05-21 2019-11-29 江苏恒瑞医药股份有限公司 A kind of purposes of the antibody combined radiotherapy of anti-PD-1 in the drug of preparation treatment tumor patient
TWI806870B (en) * 2018-05-23 2023-07-01 中國大陸商大有華夏生物醫藥集團有限公司 Anti-pd-1 antibodies and uses thereof
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (en) 2018-06-01 2019-12-31 Novartis Ag BINDING MOLECULES AGAINST BCMA AND USES OF THEM
CN108636356A (en) * 2018-06-05 2018-10-12 吉林农业大学 A kind of cornstalk biological charcoal and restorative procedure that can repair nitrogen phosphorus pollution of area source
KR20210023983A (en) 2018-06-18 2021-03-04 이나뜨 파르마 Compositions and methods for treating cancer
KR20210024550A (en) 2018-06-23 2021-03-05 제넨테크, 인크. PD-1 axis binding antagonist, platinum agent, and method of treating lung cancer using topoisomerase II inhibitor
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
KR20210034613A (en) 2018-07-18 2021-03-30 치아타이 티안큉 파마수티컬 그룹 주식회사 Drug combinations of quinoline derivatives and antibodies
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
CN112424231B (en) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 anti-PD-1 antibodies and dosages and uses thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
JP2021532143A (en) 2018-07-26 2021-11-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
CN110790839B (en) * 2018-08-03 2023-05-12 江苏恒瑞医药股份有限公司 anti-PD-1 antibody, antigen binding fragment thereof and medical application thereof
WO2020037092A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
JP2021534180A (en) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. Substituted 4-amino-1H-imidazole [4,5-c] quinoline compound and improved method for its production
AU2019323435A1 (en) * 2018-08-20 2021-02-18 Jiangsu Hengrui Medicine Co., Ltd. Use of TIM-3 antibody in preparation of medicines for treating tumors
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
TW202024023A (en) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
CN112839962A (en) 2018-10-09 2021-05-25 百时美施贵宝公司 Anti-MERTK antibodies for cancer treatment
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
HRP20241325T1 (en) 2018-10-19 2024-12-20 Bristol-Myers Squibb Company Combination therapy for melanoma
WO2020086724A1 (en) 2018-10-23 2020-04-30 Bristol-Myers Squibb Company Methods of treating tumor
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
KR20210089168A (en) 2018-11-06 2021-07-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Use of an anti-PD-1 antibody in combination with pamitinib in the manufacture of a medicament for the treatment of tumors
KR20210092769A (en) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 Anti-NKG2A antibodies and uses thereof
KR20210098504A (en) 2018-12-04 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 Analytical Methods Using In-Sample Calibration Curves by Monitoring Multiple Isotope Responses
CN113490499A (en) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer
CA3117710A1 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
MX2021007392A (en) 2018-12-20 2021-08-24 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives.
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
EP3898675A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
CN111349162A (en) * 2018-12-21 2020-06-30 神州细胞工程有限公司 Humanized anti-PD-1 antibodies and uses thereof
MX2021007271A (en) 2018-12-21 2021-07-15 Onxeo New conjugated nucleic acid molecules and their uses.
CA3119582A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1.beta. binding antibodies
WO2020136133A1 (en) 2018-12-23 2020-07-02 F. Hoffmann-La Roche Ag Tumor classification based on predicted tumor mutational burden
CN111423510B (en) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 Recombinant anti-human PD-1 antibody and application thereof
JP7506079B2 (en) 2019-01-14 2024-06-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Heterocyclic nlrp3 modulators for use in the treatment of cancer - Patents.com
US12187706B2 (en) 2019-01-14 2025-01-07 Innate Tumor Immunity, Inc. NLRP3 modulators
KR20210116529A (en) 2019-01-14 2021-09-27 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 modulators
KR20210114983A (en) 2019-01-14 2021-09-24 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 modulators
WO2020150152A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
JP2022518236A (en) 2019-01-21 2022-03-14 サノフイ Therapeutic RNA and anti-PD1 antibody for advanced solid tumor cancer
CA3128104A1 (en) * 2019-02-03 2020-08-06 Jiangsu Hengrui Medicine Co., Ltd. Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
EP3923940A1 (en) 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
ES2982474T3 (en) 2019-02-15 2024-10-16 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-1,6-dione derivatives and their uses
EA202192019A1 (en) 2019-02-15 2021-11-02 Новартис Аг DERIVATIVES OF 3- (1-OXO-5- (PIPERIDIN-4-YL) ISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND ROUTES OF THEIR APPLICATION
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
KR20210146348A (en) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
KR20210146349A (en) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
KR20220002967A (en) 2019-04-19 2022-01-07 제넨테크, 인크. Anti-MERTK antibodies and methods of use thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
JP7530913B2 (en) 2019-04-23 2024-08-08 イナート・ファルマ・ソシエテ・アノニム CD73 blocking antibodies
AU2020267491A1 (en) 2019-05-06 2021-12-02 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
US20220313685A1 (en) 2019-05-10 2022-10-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative and antibody soft tissue sarcoma combination therapy
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
KR20220011647A (en) 2019-05-20 2022-01-28 치아타이 티안큉 파마수티컬 그룹 주식회사 Quinoline derivatives for combined treatment of small cell lung cancer
AU2020278733A1 (en) 2019-05-23 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivatives for treatment of head and neck cancer
CN113874036A (en) 2019-05-24 2021-12-31 辉瑞公司 Combination therapy with CDK inhibitors
CN114174537A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Cell localization features and combination therapies
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
TW202434297A (en) 2019-07-05 2024-09-01 日商小野藥品工業股份有限公司 Treatment of hematological cancer with pd-1/cd3 bispecific protein
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
JP2022545741A (en) 2019-08-30 2022-10-28 アジェナス インコーポレイテッド ANTI-CD96 ANTIBODY AND METHODS OF USE THEREOF
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
BR112022004316A2 (en) 2019-09-22 2022-06-21 Bristol Myers Squibb Co Quantitative spatial characterization for lag-3 antagonist therapy
US20220339249A1 (en) 2019-09-25 2022-10-27 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
GB201914747D0 (en) * 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
BR112022007376A2 (en) 2019-10-21 2022-07-05 Novartis Ag COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
EP4055392A1 (en) 2019-11-05 2022-09-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
AU2020380384A1 (en) 2019-11-08 2022-05-26 Bristol-Myers Squibb Company LAG-3 antagonist therapy for melanoma
JP7629916B2 (en) 2019-11-13 2025-02-14 ジェネンテック， インコーポレイテッド Therapeutic Compounds and Methods of Use
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
CN114728941A (en) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
US20210228676A1 (en) 2019-12-09 2021-07-29 Seagen Inc. Combination Therapy With LIV1-ADC and PD-1 Antagonist
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CN113004408B (en) * 2019-12-20 2022-07-01 广东菲鹏制药股份有限公司 Anti-human apoptosis factor-1 monoclonal antibody
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4087842A1 (en) 2020-01-10 2022-11-16 Innate Tumor Immunity, Inc. Nlrp3 modulators
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115397859A (en) 2020-01-30 2022-11-25 Ona疗法有限公司 Combination therapy for the treatment of cancer and cancer metastasis
BR112022015077A2 (en) 2020-01-31 2022-10-04 Genentech Inc METHODS TO INDUCE NEOEPITOPE-SPECIFIC CD8+ T CELLS IN AN INDIVIDUAL WITH A TUMOR AND TO INDUCE CD8+ T CELL TRAFFICKING, RNA VACCINES, RNA VACCINE FOR USE AND BINDING ANTAGONISTS
CN115362167A (en) 2020-02-06 2022-11-18 百时美施贵宝公司 IL-10 and uses thereof
WO2021171260A2 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
KR20220151637A (en) 2020-03-06 2022-11-15 셀젠 콴티셀 리서치, 인크. Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or SQNSCLC
JP2023519254A (en) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー Anti-CCR8 Antibodies for Treating Cancer
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US11673879B2 (en) 2020-03-31 2023-06-13 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
WO2021203769A1 (en) * 2020-04-10 2021-10-14 江苏恒瑞医药股份有限公司 Use of anti-pd-1 antibody in preparation of drugs for treating acral lentiginous melanoma
MX2022013031A (en) 2020-04-21 2023-01-04 Novartis Ag Dosing regimen for treating a disease modulated by csf-1r.
EP4165041A1 (en) 2020-06-10 2023-04-19 Theravance Biopharma R&D IP, LLC Naphthyridine derivatives useful as alk5 inhibitors
TW202214857A (en) 2020-06-19 2022-04-16 法商昂席歐公司 New conjugated nucleic acid molecules and their uses
MX2022015852A (en) 2020-06-23 2023-01-24 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6- dione derivatives.
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN115867316A (en) * 2020-07-31 2023-03-28 江苏恒瑞医药股份有限公司 anti-PD-1 antibody pharmaceutical composition and application thereof
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN111705038B (en) * 2020-08-24 2020-11-03 江苏集萃药康生物科技有限公司 Construction method and application of cell strain capable of stably expressing human PDL1/CD73 protein
CA3193421A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CA3189987A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
AR123585A1 (en) 2020-09-24 2022-12-21 Merck Sharp & Dohme STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF
CN112285352A (en) * 2020-10-02 2021-01-29 朱吉安 Method for measuring biological activity of anti-PD-1 monoclonal antibody
EP4225770A1 (en) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
KR20230098279A (en) 2020-10-28 2023-07-03 이케나 온콜로지, 인코포레이티드 Combinations of PDX inhibitors or doxorubicin with AHR inhibitors
MX2023005131A (en) 2020-11-04 2023-05-25 Genentech Inc Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates.
MX2023005130A (en) 2020-11-04 2023-05-25 Genentech Inc Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies.
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
JP2023549581A (en) 2020-11-17 2023-11-27 シージェン インコーポレイテッド Method of treating cancer with a combination of tucatinib and anti-PD-1/anti-PD-L1 antibodies
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
KR20230117162A9 (en) 2020-12-02 2024-03-21 제넨테크, 인크. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN116723854A (en) 2021-01-22 2023-09-08 门德斯有限公司 Tumor vaccination methods
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN117858719A (en) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 Methods of dosing and treatment using a combination of checkpoint inhibitor therapy and CAR T cell therapy
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
KR20230170039A (en) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Amino-substituted heterocycles for treating cancer with EGFR mutations
CN117321078A (en) 2021-04-30 2023-12-29 豪夫迈·罗氏有限公司 Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CA3218786A1 (en) 2021-05-25 2022-12-01 Lifei HOU C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
WO2022256534A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
BR112023026966A2 (en) 2021-07-02 2024-03-12 Hoffmann La Roche METHODS FOR TREATING AN INDIVIDUAL WITH MELANOMA, FOR ACHIEVING A CLINICAL RESPONSE, FOR TREATING AN INDIVIDUAL WITH NON-HODGKIN LYMPHOMA, FOR TREATING A POPULATION OF INDIVIDUALS WITH NON-HODGKIN LYMPHOMA, AND FOR TREATING AN INDIVIDUAL WITH METASTATIC COLORECTAL CANCER
MX2024000674A (en) 2021-07-13 2024-02-07 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer.
CN118871463A (en) 2021-07-28 2024-10-29 基因泰克公司 Methods and compositions for treating cancer
IL309120A (en) 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for treating cancer
MX2024001415A (en) 2021-07-30 2024-02-27 Ona Therapeutics S L Anti-cd36 antibodies and their use to treat cancer.
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202327595A (en) 2021-10-05 2023-07-16 美商輝瑞大藥廠 Combinations of azalactam compounds for the treatment of cancer
JP2024536383A (en) 2021-10-06 2024-10-04 ジェンマブ エー／エス Multispecific binding agents to PD-L1 and CD137 in combination
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
MX2024005722A (en) 2021-11-12 2024-05-28 Novartis Ag Combination therapy for treating lung cancer.
TW202332429A (en) 2021-11-24 2023-08-16 美商建南德克公司 Therapeutic compounds and methods of use
TW202340212A (en) 2021-11-24 2023-10-16 美商建南德克公司 Therapeutic compounds and methods of use
CA3240558A1 (en) 2021-12-16 2023-06-22 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
AU2023213937A1 (en) 2022-01-26 2024-07-18 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
KR20240153583A (en) 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 Combination therapy for colorectal cancer
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
CN118871451A (en) 2022-03-18 2024-10-29 百时美施贵宝公司 Methods for separating peptides
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
EP4487226A1 (en) 2022-04-08 2025-01-08 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
IL316738A (en) 2022-05-11 2024-12-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4522657A1 (en) 2022-05-12 2025-03-19 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR20250022049A (en) 2022-06-07 2025-02-14 제넨테크, 인크. Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody
CN119585308A (en) 2022-07-13 2025-03-07 基因泰克公司 Administration of anti-FCRH5/anti-CD3 bispecific antibodies for treatment
TW202413433A (en) 2022-07-19 2024-04-01 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
AU2023313118A1 (en) 2022-07-27 2025-03-06 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
TW202440157A (en) 2022-12-01 2024-10-16 英商梅迪繆思有限公司 Combination therapy for treatment of cancer
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
WO2024175699A1 (en) 2023-02-23 2024-08-29 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
TW202448949A (en) 2023-05-05 2024-12-16 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5159730A (en) 1974-10-24 1976-05-25 Furukawa Electric Co Ltd Sutenresu no nitsukerumetsukiho
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1080311A (en) 1992-06-14 1994-01-05 江苏省盐城市师范专科学校科技部 A kind of smoke-stopping fireproofing material
JPH07291996A (en) 1994-03-01 1995-11-07 Yuu Honshiyo Polypeptide related to programmed cell death in human, dna coding the same, vector consisting of the same dna, host cell transformed with the same vector, antibody of the same polypeptide and pharmaceutical composition containing the same polypeptide or the same antibody
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045332A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
BR0013581A (en) 1999-08-23 2002-07-02 Dana Faber Cancer Inst Inc Pd-1, a receiver for b7-4, and uses for it
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
PT1537878E (en) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Immunopotentiating compositions
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2397355T5 (en) 2005-06-08 2020-11-10 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections and cancer by inhibition of the programmed cell death pathway (PD-1)
CN105056226A (en) 2006-12-27 2015-11-18 埃默里大学 Compositions and methods for the treatment of infections and tumors
EP4119579A1 (en) 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
ME02093B (en) * 2007-06-18 2014-04-30 N V Organon Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5945096B2 (en) 2008-07-04 2016-07-05 小野薬品工業株式会社 Use of a determination marker for optimizing the therapeutic effect of anti-human PD-1 antibody on cancer
US8114845B2 (en) 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
BRPI0917891A2 (en) 2008-08-25 2015-11-24 Amplimmune Inc pd-1 antagonists and methods of using them
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
CA2738252C (en) 2008-09-26 2018-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
KR101900953B1 (en) 2008-10-02 2018-09-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD86 Antagonist multi-target binding proteins
BRPI0921321A2 (en) 2008-11-28 2018-10-16 Emory University methods for the treatment of tumors and tumors
SG10201610247QA (en) 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
JP5714505B2 (en) * 2008-12-22 2015-05-07 ノヴォ ノルディスク アー／エス Antibodies against tissue factor pathway inhibitor
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
US8709417B2 (en) 2009-09-30 2014-04-29 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CA2790134A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CA2801210C (en) * 2010-06-19 2020-07-21 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
JP5996438B2 (en) 2010-12-22 2016-09-21 国立大学法人 岡山大学 Method for testing chronic inflammatory disease using antibody to inhibitory costimulatory molecule as marker
WO2012113064A1 (en) 2011-02-25 2012-08-30 Bc Cancer Agency Branch Method of diagnosing primary mediastinal b-cell lymphoma or classical hodgkin lymphoma by detecting functional mutation at ciita locus.
CN103429264A (en) 2011-03-31 2013-12-04 默沙东公司 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
BR122022000334B1 (en) 2011-08-01 2023-03-21 Genentech, Inc PHARMACEUTICAL COMPOSITION COMPRISING A PD-1 AXIS BINDING ANTAGONIST AND A MEK INHIBITOR
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
US9863935B2 (en) 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EA037351B8 (en) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Method of treating cancer using an anti-pd-1 and anti-ctla-4 antibody combination
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014043708A1 (en) 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
SG10202011046RA (en) 2012-09-21 2020-12-30 Intensity Therapeutics Inc Method of treating cancer
ES2643887T3 (en) 2012-10-02 2017-11-27 Bristol-Myers Squibb Company Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
EP2906241B1 (en) 2012-10-12 2020-01-08 The Brigham and Women's Hospital, Inc. Enhancement of the immune response
US9828428B2 (en) * 2012-11-07 2017-11-28 Pfizer Inc. Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
US20140147411A1 (en) 2012-11-14 2014-05-29 U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS Methods of treating cancer and testing mutation zygosity related thereto
WO2014100542A1 (en) * 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
ES2721168T3 (en) 2013-01-11 2019-07-29 Dingfu Biotarget Co Ltd Agents to treat tumors, use and method thereof
JP6456305B2 (en) 2013-02-22 2019-01-23 キュアバック アーゲー Combination of vaccination and PD-1 pathway inhibition
MY180687A (en) 2013-03-14 2020-12-07 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP2970473B1 (en) 2013-03-14 2017-08-16 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
EP2970499B1 (en) * 2013-03-15 2022-08-10 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
EP3004169B1 (en) 2013-05-31 2023-03-22 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN105658206A (en) 2013-06-03 2016-06-08 诺华股份有限公司 Combinations of anti-pd-l1 antibody and mek inhibitor and/or braf inhibitor
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
RU2016107426A (en) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. COMBINING CD27 AGONISTS AND INHIBITING IMMUNE CONTROL POINTS TO STIMULATE IMMUNITY
US20160194369A1 (en) 2013-08-12 2016-07-07 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of inerest and il6
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
JP2016530267A (en) 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ Immune receptor modulation to treat cancer and viral infections
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
CN107090041B (en) 2013-09-13 2018-11-16 百济神州有限公司 Anti- PD1 antibody and its purposes as therapeutic agent and diagnosticum
PT3508502T (en) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
CN104558177B (en) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 Monoclonal antibody for antagonizing and inhibiting programmed death receptor PD-1and ligand combination thereof, and coding sequence and application thereof
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
WO2015069770A1 (en) 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
NZ719232A (en) 2013-11-05 2022-04-29 Bavarian Nordic As Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
EP3074035B1 (en) 2013-11-25 2020-05-13 FameWave Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
EP3079699A4 (en) 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2015094995A2 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
RS59659B2 (en) 2013-12-17 2023-08-31 Hoffmann La Roche PD-1 AXIS BINDING ANTAGONISTS AND TAXANE-ASSISTED CANCER TREATMENTS
US20160304969A1 (en) 2013-12-17 2016-10-20 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
US20160312297A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EA201691376A1 (en) 2014-02-04 2017-01-30 Пфайзер Инк. COMBINATION OF ANTAGONIST PD-1 AND VEGFR INHIBITOR FOR CANCER TREATMENT
PT3134123T (en) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
WO2015127158A1 (en) 2014-02-21 2015-08-27 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
CN106255510A (en) 2014-03-05 2016-12-21 百时美施贵宝公司 Use the combined therapy renal carcinoma of anti-PD 1 antibody and another anticarcinogen
KR102248804B1 (en) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
SI3116909T1 (en) 2014-03-14 2020-03-31 Novartis Ag Antibody molecules to lag-3 and uses thereof
US20170020931A1 (en) 2014-03-31 2017-01-26 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
CN104974253A (en) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
CN106714839A (en) 2014-05-15 2017-05-24 百时美施贵宝公司 Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
CN105085680A (en) 2014-05-23 2015-11-25 复旦大学 Humanized anti-PD-1 and c-MET bispecific antibody, and preparation method and application thereof
SG11201609468WA (en) 2014-05-29 2016-12-29 Medimmune Ltd Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
EP3156072B1 (en) 2014-06-11 2020-08-19 IDAC Theranostics, Inc. Method for reducing side effects of immune checkpoint control agent
WO2015192068A1 (en) 2014-06-12 2015-12-17 The Johns Hopkins University Combinatorial immunotherapy for pancreatic cancer treatment
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EP3166975A1 (en) 2014-07-07 2017-05-17 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
JP6626085B2 (en) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods for suppressing bone marrow-derived suppressor cells and inhibiting immune checkpoints
DK3169341T3 (en) 2014-07-16 2019-08-05 Transgene Sa ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUN CHECKPOINT MODULATORS
KR20170052569A (en) 2014-07-18 2017-05-12 어드박시스, 인크. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
RU2711141C2 (en) 2014-07-22 2020-01-15 СиБи ТЕРЕПЬЮТИКС, ИНК. Anti-pd-1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016014799A1 (en) 2014-07-23 2016-01-28 University Of Iowa Research Foundation Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
CN105330740B (en) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 Anti- PD-1 antibody and its application
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
EP3179992B1 (en) 2014-08-11 2022-05-11 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
CN114099671A (en) 2014-08-12 2022-03-01 鳄鱼生物科学公司 Combination therapy with anti-CD 40 antibodies
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
MX2017002134A (en) 2014-08-19 2017-09-13 Nat Univ Corporation Okayama Univ Method for enhancing immune cell function and method for assessing immune cell multifunctionality.
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
DK3186281T3 (en) 2014-08-28 2019-06-11 Halozyme Inc Combination therapy with a hyaluronan degrading enzyme and an immuno-checkpoint inhibitor
CA2960490A1 (en) 2014-09-08 2016-03-17 Celgene Corporation Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
MX2017003227A (en) 2014-09-13 2017-12-04 Novartis Ag Combination therapies of alk inhibitors.
WO2016044207A1 (en) 2014-09-15 2016-03-24 The Johns Hopkins University Biomarkers useful for determining response to pd-1 blockade therapy
CA2957491A1 (en) 2014-09-16 2016-03-24 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR102659538B1 (en) 2014-09-28 2024-04-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 Modulation of stimulatory and non-stimulatory myeloid cells
BR112017006664A2 (en) 2014-10-03 2017-12-26 Novartis Ag combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
SG11201702934TA (en) 2014-10-14 2017-05-30 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
SMT202100164T1 (en) 2014-10-29 2021-05-07 Bristol Myers Squibb Co Combination therapy for cancer
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US20190119353A1 (en) 2014-11-06 2019-04-25 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
MY191423A (en) 2014-11-10 2022-06-27 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
JP2018500384A (en) 2014-11-11 2018-01-11 メディミューン リミテッド Combination of treatments to treat tumor formation
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
SG10201914022QA (en) 2014-11-13 2020-03-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
BR112017010198A2 (en) 2014-11-17 2017-12-26 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
RU2753902C2 (en) 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Combination therapy based on t-cell-activating bispecific antigen-binding molecules against cd3 and folate receptor 1 (folr1) and antagonists binding to pd-1 axis
MA40737A (en) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
EP3226856A4 (en) 2014-12-02 2018-07-11 Celgene Corporation Combination therapies
KR20170088984A (en) 2014-12-04 2017-08-02 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
WO2016090300A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
AU2015360642B2 (en) 2014-12-08 2019-04-04 1Globe Biomedical Co., Ltd. Soluble universal ADCC-enhancing synthetic fusion gene and peptide technology and its use thereof
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
AU2015360736A1 (en) 2014-12-09 2017-06-01 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
US20180133313A1 (en) 2014-12-16 2018-05-17 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CA2971734A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Anti-pd-1 antibodies
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
ES2856844T3 (en) 2014-12-31 2021-09-28 Checkmate Pharmaceuticals Inc Combined antitumor immunotherapy
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
EP3244927A1 (en) 2015-01-16 2017-11-22 Vedantra Pharmaceuticals Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
CN105983097B (en) 2015-01-28 2021-06-08 华中科技大学同济医学院附属协和医院 A kind of antitumor preparation and preparation method thereof
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
EP3253413A2 (en) 2015-02-06 2017-12-13 Kadmon Corporation, LLC Immunomodulatory agents
CN104987421A (en) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 Anti-CTLA-4 and PD-1 dual variable domain immunoglobulin
WO2017054646A1 (en) * 2015-09-28 2017-04-06 江苏恒瑞医药股份有限公司 Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
CN105175545B (en) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 An anti-VEGF-anti-PD-1 bifunctional antibody and its application
CN105754990A (en) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody
TWI764943B (en) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer
CN109806393B (en) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, pemetrexed and platinum drugs in combined treatment of non-small cell lung cancer
KR102224556B1 (en) * 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Antibodies against T cell immune receptors (TIGIT) with IG and ITIM domains and their use

Also Published As

Publication number Publication date
TW201605901A (en) 2016-02-16
CN105026428B (en) 2018-01-16
PH12016501120A1 (en) 2016-08-15
IL246137A0 (en) 2016-07-31
KR20160113113A (en) 2016-09-28
CR20160319A (en) 2016-11-08
EP3081576A4 (en) 2017-07-05
HUE046249T2 (en) 2020-02-28
DOP2016000133A (en) 2016-11-30
SI3081576T1 (en) 2019-12-31
CY1122245T1 (en) 2020-11-25
MY184154A (en) 2021-03-23
WO2015085847A1 (en) 2015-06-18
CL2016001460A1 (en) 2017-01-20
EP3081576B1 (en) 2019-08-21
SG10201804945WA (en) 2018-07-30
HRP20191678T1 (en) 2019-12-13
MX370449B (en) 2019-12-13
PT3081576T (en) 2019-10-15
RS59480B1 (en) 2019-12-31
AU2014361473B2 (en) 2019-09-26
JP6502959B2 (en) 2019-04-17
PE20160953A1 (en) 2016-09-26
LT3081576T (en) 2019-10-25
NZ721624A (en) 2021-10-29
ZA201604660B (en) 2019-12-18
SMT201900591T1 (en) 2019-11-13
ME03527B (en) 2020-04-20
BR112016013338B1 (en) 2023-11-21
JP2017500889A (en) 2017-01-12
EP3081576A1 (en) 2016-10-19
UA119659C2 (en) 2019-07-25
US20190309069A1 (en) 2019-10-10
PH12016501120B1 (en) 2021-06-09
US11365255B2 (en) 2022-06-21
MX2016007620A (en) 2017-01-11
PL3081576T3 (en) 2020-03-31
US10344090B2 (en) 2019-07-09
TWI654201B (en) 2019-03-21
DK3081576T3 (en) 2019-10-21
US20160376367A1 (en) 2016-12-29
AU2014361473A1 (en) 2016-07-07
CA2932966A1 (en) 2015-06-18
CN105026428A (en) 2015-11-04
BR112016013338A2 (en) 2017-09-26
EA035037B1 (en) 2020-04-21
CA2932966C (en) 2022-03-22
ES2746805T3 (en) 2020-03-06
IL246137B (en) 2020-01-30
EA201691225A1 (en) 2016-09-30
KR102256152B1 (en) 2021-05-27
HK1213910A1 (en) 2016-07-15
ECSP16060104A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
ZA201604660B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
HRP20181478T1 (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
HRP20190201T1 (en) Engineered anti-tgf-beta antibodies and antigen-binding fragments
HK1218423A1 (en) Anti-b7-h4 antibodies and immunoconjugates b7-h4
HUE052487T2 (en) Anti-pd-1 antibody and use thereof
EP3066470A4 (en) Humanized anti-ceacam5 antibody and uses thereof
EP3042956A4 (en) Antibody which specifically reacts with human integrin a6b4
HK1215959A1 (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same cdh3
HK1244828A1 (en) Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof
IL240161A0 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3